ET-1 receptor antagonists, used for the treatment of primary PHT [527], have been found to be beneficial in sickle-Antilles-hemoglobin D mice [528], indicating the important role of ET-1 in PHT in SCA. This evidence concerns the gene EDN1 and autosomal dominant cerebellar ataxia.